Financial Performance - For the six months ended September 30, 2024, the company reported revenue of HKD 30,792,000, representing an increase from HKD 30,141,000 in the same period last year, which is a growth of approximately 2.2%[14] - The gross profit for the same period was HKD 11,812,000, down from HKD 14,891,000, indicating a decrease of about 20.8%[14] - The company recorded a profit of HKD 101,459,000 for the period, a significant recovery from a loss of HKD 236,913,000 in the previous year[14] - The group recorded a profit before tax of HKD 102,376,000 for the six months ended September 30, 2024, compared to a loss of HKD 235,795,000 in the same period of 2023[64] - The net profit for the six months ended September 30, 2024, was HKD 101,459,000, a significant recovery from a net loss of HKD 236,913,000 in 2023[66] - Other income for the six months ended September 30, 2024, totaled HKD 3,032,000, slightly down from HKD 3,137,000 in 2023[69] - The group reported a fair value gain on convertible bonds of HKD 111,229,000 for the six months ended September 30, 2024, compared to a loss of HKD 225,919,000 in 2023[73] - Basic earnings per share for the six months ended September 30, 2024, were HKD 100,934,000, compared to a loss of HKD 237,725,000 in 2023[79] - The group incurred administrative expenses of HKD 5,092,000 for the six months ended September 30, 2024, slightly down from HKD 5,113,000 in 2023[58] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 1,399,449,000, an increase from HKD 1,287,189,000 as of March 31, 2024, reflecting a growth of approximately 8.7%[9] - The company's equity attributable to owners increased to HKD 1,216,476,000 from HKD 1,113,125,000, marking a rise of about 9.3%[5] - The company reported a net cash position of HKD 934,770,000, significantly up from HKD 177,442,000 in the previous period[10] - The company’s non-current liabilities increased to HKD 132,959,000 from HKD 123,206,000, reflecting a rise of approximately 6.2%[7] - The group's total debt to total assets ratio was 0.09, with total assets of approximately HKD 1,399,400,000 and total liabilities of approximately HKD 130,200,000 as of September 30, 2024[108] Revenue Segments - The manufacturing segment generated revenue of HKD 30,772,000 for the six months ended September 30, 2024, up from HKD 30,135,000 in 2023, reflecting a growth of 2.1%[53] - The trading segment reported revenue of HKD 20,000 for the six months ended September 30, 2024, significantly up from HKD 6,000 in 2023, marking a substantial increase of 233.3%[53] Investments and Fair Value - As of September 30, 2024, the fair value of convertible bond investments was HKD 771,793,000, compared to HKD 660,564,000 as of March 31, 2024, representing an increase of 16.8%[25] - The fair value change of convertible bond investments for the six months ended September 30, 2023, showed an unrealized loss of HKD 290,826,000[33] - The fair value of the convertible bonds as of July 12, 2023, was HKD 502,704,000, reflecting a significant valuation adjustment[34] - The company recorded an unrealized gain of approximately HKD 111.2 million from the fair value changes of the convertible bond investment during the interim period of 2024, compared to an unrealized loss of approximately HKD 225.9 million in the same period of 2023[99] Operational Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] - The company plans to strengthen internal management and enhance production and sales efficiency to improve market competitiveness and drive profit growth[90] - The company aims to monitor market trends and seize potential long-term development opportunities despite challenges in the pharmaceutical market[91] Employee and Administrative Costs - The employee costs for the interim period amounted to approximately HKD 10,900,000, an increase from HKD 10,200,000 in the same period last year[113] - The company's administrative, sales, and distribution expenses totaled approximately HKD 14,800,000, a decrease of about HKD 3,400,000 or 18.5% compared to HKD 18,200,000 in the previous period[88] - Selling and distribution expenses decreased by approximately HKD 2.3 million or 34.6% to about HKD 4.4 million during the interim period of 2024, due to cost control and increased sales efficiency[102] - Administrative expenses decreased by approximately HKD 1.1 million or 9.2% to about HKD 10.4 million during the interim period of 2024, attributed to streamlined operations and reduced legal and professional fees[103] Dividend Policy - The group did not recommend the payment of an interim dividend for the six months ended September 30, 2024, consistent with no dividend declared for the same period in 2023[78] - The group has no established dividend policy, opting instead to determine dividends based on financial performance and capital needs[118] Staff and Employment - The group employed 162 staff as of September 30, 2024, down from 169 staff a year earlier[113] - The group has not conducted any buybacks, redemptions, or sales of its listed securities during the interim period[120] Compliance and Reporting - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim financial information and confirmed compliance with current Hong Kong accounting practices[122] - The interim results announcement has been published on the Hong Kong Stock Exchange and the company's website, with printed copies available upon request[123]
精优药业(00858) - 2025 - 中期业绩